Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Moderna, Inc. is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) technology. The company operates primarily within the biopharmaceutical and life sciences industries, leveraging its proprietary mRNA platform to design therapies and vaccines that instruct cells to produce proteins for disease prevention or treatment. Moderna’s core revenue historically has been driven by its COVID-19 vaccine, Spikevax, with an expanding pipeline targeting infectious diseases, oncology, cardiovascular disease, and rare genetic disorders.
Founded in 2010, Moderna was established to commercialize advances in mRNA science that enable rapid drug development and scalable manufacturing. The company evolved from a research-stage biotech into a commercial-stage pharmaceutical company following the global deployment of its COVID-19 vaccine beginning in 2020. Moderna positions itself as a platform company, emphasizing speed, flexibility, and digital integration across research, development, and manufacturing as key strategic advantages.
Business Operations
Moderna generates revenue primarily through the development, manufacturing, and commercialization of mRNA-based vaccines and therapeutics. Its operations are organized around its mRNA platform, which includes proprietary technologies for mRNA design, lipid nanoparticle delivery systems, and integrated manufacturing capabilities. The company conducts research and development internally and advances product candidates through clinical trials, regulatory approval, and commercial distribution.
The company operates both domestically and internationally, with commercial sales largely outside the United States during the peak of COVID-19 vaccine demand. Moderna maintains strategic collaborations and partnerships with governments, global health organizations, and pharmaceutical companies to support development, manufacturing scale-up, and distribution. The company also controls in-house manufacturing facilities and has expanded its end-to-end capabilities to reduce reliance on third-party manufacturers.
Strategic Position & Investments
Moderna’s strategic direction centers on expanding its mRNA-based vaccine and therapeutic pipeline beyond COVID-19, with growth initiatives targeting respiratory vaccines, combination vaccines, cancer immunotherapies, and rare disease treatments. The company has invested heavily in late-stage clinical programs, including vaccines for respiratory syncytial virus (RSV), influenza, and personalized cancer vaccines developed in collaboration with Merck & Co.
The company has made significant capital investments in manufacturing infrastructure and digital systems to support rapid product development and global supply. Moderna has also established regional manufacturing hubs and pursued government-supported initiatives to strengthen pandemic preparedness. Emerging areas of focus include next-generation mRNA technologies, improved delivery systems, and applications of mRNA in autoimmune and cardiovascular diseases.
Geographic Footprint
Moderna is headquartered in Cambridge, Massachusetts, and operates across North America, Europe, Asia-Pacific, and other international markets. The company has commercial and manufacturing operations in the United States and Europe, with additional investments in regional manufacturing capabilities to support global vaccine access.
Internationally, Moderna has expanded its presence through subsidiaries, supply agreements, and government partnerships, including efforts to establish mRNA manufacturing capacity in Australia, Canada, and parts of Africa. Its products have been distributed across dozens of countries, giving the company a broad global footprint and significant international operational influence.
Leadership & Governance
Moderna was co-founded by Stéphane Bancel, who has played a central role in shaping the company’s platform-driven strategy and emphasis on speed and innovation. The leadership team emphasizes a data-driven, technology-focused culture with long-term investment in scientific capabilities and scalable manufacturing.
Key executives include:
- Stéphane Bancel – Chief Executive Officer
- Jamey Mock – Chief Financial Officer
- Stephen Hoge – President
- Juan Andres – Chief Technical Operations and Quality Officer
- Kate Cronin – Chief Brand Officer
The company is governed by a board with experience across biotechnology, pharmaceuticals, and global business, supporting Moderna’s focus on long-term growth, scientific innovation, and disciplined capital allocation.